The US House of Representatives has passed a bill popularly known as the Insulin Price Bill that limits insulin costs to $35 per month. These benefits will be offered from 2023 to people with insurance policy or medicare coverage. The US shares 15% of the global insulin market and accounts for almost 50% of the revenue in the pharmaceutical industry.
